Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Percheron Therapeutics ( (AU:PER) ) has issued an update.
Percheron Therapeutics has announced the final results of its Phase I clinical trial for HMBD-002. The results of this trial are significant for the company’s operations and may influence its positioning in the pharmaceutical industry, although the inherent risks and uncertainties in drug development are acknowledged.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Average Trading Volume: 3,152,884
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
Find detailed analytics on PER stock on TipRanks’ Stock Analysis page.